Your browser doesn't support javascript.
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2.
Aragão, Luiz Guilherme H S; Oliveira, Júlia T; Temerozo, Jairo R; Mendes, Mayara A; Salerno, José Alexandre; Pedrosa, Carolina S G; Puig-Pijuan, Teresa; Veríssimo, Carla P; Ornelas, Isis M; Torquato, Thayana; Vitória, Gabriela; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; da Silva Gomes Dias, Suelen; Cardoso Soares, Vinicius; Souza, Letícia R Q; Karmirian, Karina; Goto-Silva, Livia; Biagi, Diogo; Cruvinel, Estela M; Dariolli, Rafael; Furtado, Daniel R; Bozza, Patrícia T; Borges, Helena L; Souza, Thiago M L; Guimarães, Marília Zaluar P; Rehen, Stevens K.
  • Aragão LGHS; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Oliveira JT; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Temerozo JR; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Mendes MA; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Salerno JA; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Pedrosa CSG; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Puig-Pijuan T; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Veríssimo CP; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Ornelas IM; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Torquato T; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Vitória G; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Sacramento CQ; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Fintelman-Rodrigues N; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • da Silva Gomes Dias S; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Cardoso Soares V; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Souza LRQ; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Karmirian K; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Goto-Silva L; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Biagi D; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Cruvinel EM; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Dariolli R; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Furtado DR; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Bozza PT; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Borges HL; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.
  • Souza TML; Pluricell Biotech, São Paulo, São Paulo, Brazil.
  • Guimarães MZP; Pluricell Biotech, São Paulo, São Paulo, Brazil.
  • Rehen SK; Pluricell Biotech, São Paulo, São Paulo, Brazil.
PeerJ ; 9: e12262, 2021.
Article in English | MEDLINE | ID: covidwho-1468712
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can infect several organs, especially impacting respiratory capacity. Among the extrapulmonary manifestations of COVID-19 is myocardial injury, which is associated with a high risk of mortality. Myocardial injury, caused directly or indirectly by SARS-CoV-2 infection, can be triggered by inflammatory processes that lead to damage to the heart tissue. Since one of the hallmarks of severe COVID-19 is the "cytokine storm", strategies to control inflammation caused by SARS-CoV-2 infection have been considered. Cannabinoids are known to have anti-inflammatory properties by negatively modulating the release of pro-inflammatory cytokines. Herein, we investigated the effects of the cannabinoid agonist WIN 55,212-2 (WIN) in human iPSC-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. WIN did not modify angiotensin-converting enzyme II protein levels, nor reduced viral infection and replication in hiPSC-CMs. On the other hand, WIN reduced the levels of interleukins six, eight, 18 and tumor necrosis factor-alpha (TNF-α) released by infected cells, and attenuated cytotoxic damage measured by the release of lactate dehydrogenase (LDH). Our findings suggest that cannabinoids should be further explored as a complementary therapeutic tool for reducing inflammation in COVID-19 patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: PeerJ Year: 2021 Document Type: Article Affiliation country: Peerj.12262

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: PeerJ Year: 2021 Document Type: Article Affiliation country: Peerj.12262